Endothelin Receptor Antagonism: A New Era in the Treatment of Pulmonary Arterial Hypertension

Abstract The endothelin system has been extensively studied over the last several years. It is clear that endothelin-1 (ET-1) is a key mediator in pulmonary vascular biology and physiology. Abnorma...

[1]  D. Badesch,et al.  Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study , 2001, The Lancet.

[2]  C. Pedersen,et al.  Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension. , 2000, The European respiratory journal.

[3]  B. Groves,et al.  Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension. , 1999, Circulation.

[4]  Yue-ying Gu,et al.  Pulmonary hypertension in systemic lupus erythematosus , 1999, Rheumatology International.

[5]  G. Karabıyıkoğlu,et al.  Local and Peripheral Plasma Endothelin-1 in Pulmonary Hypertension Secondary to Chronic Obstructive Pulmonary Disease , 1998, Respiration.

[6]  Z. Li,et al.  Plasma endothelin 1 concentrations in children with congenital heart defects. , 1998, Minerva pediatrica.

[7]  D. Stewart,et al.  Human pulmonary circulation is an important site for both clearance and production of endothelin-1. , 1996, Circulation.

[8]  S. Kira,et al.  Effects of separate and combined ETA and ETB blockade on ET-1-induced constriction in perfused rat lungs. , 1995, The American journal of physiology.

[9]  G. Valesini,et al.  Plasma endothelin-1 levels, pulmonary hypertension, and lung fibrosis in patients with systemic sclerosis. , 1995, The American journal of medicine.

[10]  P. Henry,et al.  Receptors for endothelin‐1 in asthmatic human peripheral lung , 1995, British journal of pharmacology.

[11]  M. Yacoub,et al.  Localization and Characterization of Endothelin‐1 Binding Sites in the Transplanted Human Lung , 1995, Journal of cardiovascular pharmacology.

[12]  A. Davenport,et al.  Characterization of Endothelin Receptors in the Human Pulmonary Vasculature Using Bosentan, SB209670, and 97–139 , 1995, Journal of cardiovascular pharmacology.

[13]  M. Sheppard,et al.  Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis , 1993, The Lancet.

[14]  D. Stewart,et al.  Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. , 1993, The New England journal of medicine.

[15]  P. Binkley,et al.  Plasma Endothelin Correlates With the Extent of Pulmonary Hypertension in Patients With Chronic Congestive Heart Failure , 1992, Circulation.

[16]  D. Stewart,et al.  Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? , 1991, Annals of internal medicine.

[17]  A. Davenport,et al.  Endothelin-1 mRNA is widely expressed in porcine and human tissues. , 1990, The Journal of clinical investigation.

[18]  J. Vane,et al.  Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. , 1988, Proceedings of the National Academy of Sciences of the United States of America.